List view / Grid view
The global small molecule drug discovery market is set for significant growth. Explore the key factors driving this expansion, from rising R&D investments to the increasing role of AI and CROs.
In this Q&A, Krishna Polu and Dennis Pedersen, senior leaders of Commit Biologics, which is backed by Novo Holdings and Bioqube Ventures, elucidate how their technology differs from other existing therapeutic platforms and highlight its implications for the treatment of both cancer and autoimmune disease.
Discover how Cue Biopharma harnesses the curative potential of the body’s intrinsic immune system to develop treatments for oncology and autoimmune diseases. Here, Anish Suri, Chief Scientific Officer of Cue Biopharma, explains how its platforms and biologics are designed to selectively modulate disease-specific T cells to restore immune balance, aiming…
Researchers for the first time have captured images of an autoantibody bound to a nerve cell surface receptor, revealing the physical mechanism behind a neurological autoimmune disease.
Researchers have developed a new bioinformatics pipeline that could help investigate the mechanism underlying the development of autoimmune diseases following SARS-CoV-2 infection.
In a world first, researchers have grown immune cells from pluripotent stem cells in a dish, which could be used to develop immunotherapies or to test autoimmune disease treatments.
Researchers have used a drug candidate to block a receptor that contributes to the development of autoimmune disease which could be a potential treatment.
Phospholipid-reactive T-cells that are able to recognise phospholipids could help in treatments against cancer, autoimmune diseases and dyslipidemia...
